A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus
Launched by JONG WOO CHUNG · Jun 21, 2011
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
1. Clinical research methods
* Determination of eligibility by history taking, physical examination, pure tone audiometry, speech audiometry, and distortion product otoacoustic emission test.
* Randomization by random sequence generation
* Administration : cilostazol 100mg Bid 4 weeks for the study group and placebo tablet Bid 4 weeks for the control group.
* Evaluation battery: questionnaires (tinnitus handicap inventory, visual analogue scale, Quality of life SF-36)
* Time of evaluation : pre-administration, 2 weeks after administration, 4 week after administration
* Mo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults of age over 19
- • Unilateral or bilateral tinnitus
- • Chronic tinnitus lasting more than 3 months
- • Initial visual analogue scale of tinnitus \>3
- Exclusion Criteria:
- • Conductive hearing loss on pure tone audiometry
- • Associated other inner ear diseases such as Meniere's disease
- • Objective or pulsatile tinnitus
- • Contraindication to anti-platelet drug
- • Any cardiac disease
- • Bleeding tendency and major operation within 3 months
- • Breastfeeding
- • Pregnancy
About Jong Woo Chung
Jong Woo Chung is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and innovation. With a focus on developing effective therapeutic solutions, the organization collaborates with leading researchers and institutions to conduct rigorous clinical trials across various therapeutic areas. Jong Woo Chung prioritizes patient safety and adherence to ethical standards, ensuring that all studies are designed and executed with the highest level of scientific integrity. Their mission is to contribute to the development of groundbreaking treatments that improve patient outcomes and enhance quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Jong Woo Chung, M.D.
Principal Investigator
Asan Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials